Neuro-oncology Certification Examination Committee Contributors
David M. Cachia, MD, Chair, UMass Memorial Medical Center
Disclosures: Receives personal compensation for serving as Bayer USA advisory board member.
Christian Grommes, MD, Vice Chair, Memorial Sloan Kettering Cancer Center
Disclosures: Receives personal compensation for serving on advisory board for BTG, Kite, and Ono. Received grant funding for research from Bayer, BMS, BTG, and Pharmacyclics.
Joy E. Burke, MD, Beth Israel Lahey Health, Lahey Clinic
Disclosures: Nothing to disclose.
Yasmin Khakoo, MD, Memorial Sloan Kettering Cancer Center
Disclosures: Receives personal compensation for serving as Editor-in-Chief for Pediatric Neurology (Elsevier). Receives grant funding for research from Nevus Outreach, Inc. (nonprofit, tax-exempt organization).
Heather E. Leeper, MD, National Institute of Health – National Cancer Institute
Disclosures: Nothing to disclose.
Douglas E. Ney, MD, University of Colorado – Anschutz Medical Campus
Disclosures: Receives compensation to serve on DNAtrix Therapeutics - Data Safety Monitoring Board. Receives research support from Orbus Therapeutics – clinical trial sponsor and from Denovo Biopharm – clinical trial sponsor.
Katherine B. Peters, MD, PhD, Duke University Medical Center
Disclosures: Receives personal compensation for serving on Advisory Boards of Agios and Sapience. Received research support from Agios, Abbvie, and Biomimetix. Served on Society of Neuro-oncology Review Course for Neuro-oncology.
Roy E. Strowd, III, MD, MEd, Wake Forest Baptist Health
Disclosures: Receives consulting fees from Novocure and Monteris Medical; receives royalties from Lecturio for online lectures in neurology; receives research support from JAZZ Pharmaceuticals and Alpha Omega Alpha. Research work funded by grants from National Institutes of Health and American Board of Psychiatry and Neurology.
Joon Uhm, MD, Mayo Clinic – Rochester
Disclosures: Receives speaker fees from Zai Labs for speaking engagements at CME meetings, with topics focused on current approaches to brain tumor therapies as well as tumor treatment field device.
Andrea Wasilewski, MD, Givens Brain Tumor Center
Disclosures: Nothing to disclose.